Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 171

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

Open access
Inker, Lesley A., Collier, Willem, Greene, Tom, Miao, Shiyuan, Chaudhari, Juhi, Appel, Gerald B., Badve, Sunil V., Caravaca-Fontán, Fernando, Del Vecchio, Lucia, Floege, Jürgen, Goicoechea, Marian, Haaland, Benjamin, Herrington, William G., Imai, Enyu, Jafar, Tazeen H., Lewis, Julia B., Li, Philip K. T., Maes, Bart D., Neuen, Brendon L., Perrone, Ronald D., Remuzzi, Giuseppe, Schena, Francesco P., Wanner, Christoph, Wetzels, Jack F. M., Woodward, Mark, Heerspink, Hiddo J. L., the CKD-EPI Clinical Trials Consortium, Estacio, Raymond O., Hanratty, Rebecca, Chalmers, John, Canetta, Pietro, Barrett, Brendan, Neal, Bruce, Perkovic, Vlado, Mahaffey, Kenneth W., Johnson, David, Jardine, Meg, von Eynatten, Maximilian, Verde, Eduardo, Verdalles, Ursula, Arroyo, David, Chapman, Arlene, Torres, Vicente, Yu, Alan, Brosnahan, Godela, Hannedouche, Thierry, Chow, Kai-Ming, Szeto, Cheuk-Chun, Leung, Chi-Bon, Xie, Di, Hou, Fan Fan, Dwyer, Jamie, Pohl, Marc A., Raz, Itamar, Hunsicker, Lawrence G., Vanacker, An, Malfait, Thomas, Maschio, Giuseppe, Locatelli, Francesco, Blankestijn, Peter J., van Zuilen, Arjan, Kobayashi, Fumiaki, Makino, Hirofumi, Chan, Juliana C. N., Andrulli, Simeone, Pozzi, Claudio, Casartelli, Donatella, Praga, Manuel, Trujillo, Hernando, Cavero, Teresa, Sevillano, Angel, Ruggenenti, Piero, Perna, Annalisa, Carrara, Fabiola, Keane, William F., Manno, Carlo, Haynes, Richard, Herrington, William G., Baigent, Colin, Landray, Martin, Rauen, Thomas, Seikrit, Claudia, Wied, Stefanie, Toto, Robert D., de Jong, Paul E., Saddelli, Mauro · 2023 · Nature Medicine

Abstract

Glomerular filtration rate (GFR) decline is causally associated with kidney failure and is a candidate surrogate endpoint for clinical trials of chronic kidney disease (CKD) progression. Analyses across a diverse spectrum of interventions and populations is required for acceptance of GFR decline as an endpoint. In an analysis of individual participant data, for each of 66 studies (total of 186,312 participants), we estimated treatment effects on the total GFR slope, computed from baseline to 3 years, and chronic slope, starting at 3 months after randomization, and on the clinical endpoint (doubling of serum creatinine, GFR < 15 ml min^−1 per 1.73 m^2 or kidney failure with replacement therapy). We used a Bayesian mixed-effects meta-regression model to relate treatment effects on GFR slope with those on the clinical endpoint across all studies and by disease groups (diabetes, glomerular diseases, CKD or cardiovascular diseases). Treatment effects on the clinical endpoint were strongly associated with treatment effects on total slope (median coefficient of determination (R^2) = 0.97 (95% Bayesian credible interval (BCI) 0.82–1.00)) and moderately associated with those on chronic slope (R^2 = 0.55 (95% BCI 0.25–0.77)). There was no evidence of heterogeneity across disease. Our results support the use of total slope as a primary endpoint for clinical trials of CKD progression. A meta-analysis of individual-level patient data from 66 clinical studies supports the utility of glomerular filtration rate as a surrogate endpoint in clinical trials for chronic kidney disease, with potential to enable detection of events earlier in the disease course.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02418-0

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 171

Metadata

Authors
Inker, L. A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G. B., Badve, S. V., Caravaca-Fontán, F., Del Vecchio, L., Floege, J., Goicoechea, M., Haaland, B., Herrington, W. G., Imai, E., Jafar, T. H., Lewis, J. B., Li, P. K. T., Maes, B. D., Neuen, B. L., Perrone, R. D., Remuzzi, G., Schena, F. P., Wanner, C., Wetzels, J. F. M., Woodward, M., Heerspink, H. J. L., the CKD-EPI Clinical Trials Consortium, Estacio, R. O., Hanratty, R., Chalmers, J., Canetta, P., Barrett, B., Neal, B., Perkovic, V., Mahaffey, K. W., Johnson, D., Jardine, M., von Eynatten, M., Verde, E., Verdalles, U., Arroyo, D., Chapman, A., Torres, V., Yu, A., Brosnahan, G., Hannedouche, T., Chow, K.-M., Szeto, C.-C., Leung, C.-B., Xie, D., Hou, F. F., Dwyer, J., Pohl, M. A., Raz, I., Hunsicker, L. G., Vanacker, A., Malfait, T., Maschio, G., Locatelli, F., Blankestijn, P. J., van Zuilen, A., Kobayashi, F., Makino, H., Chan, J. C. N., Andrulli, S., Pozzi, C., Casartelli, D., Praga, M., Trujillo, H., Cavero, T., Sevillano, A., Ruggenenti, P., Perna, A., Carrara, F., Keane, W. F., Manno, C., Haynes, R., Herrington, W. G., Baigent, C., Landray, M., Rauen, T., Seikrit, C., Wied, S., Toto, R. D., de Jong, P. E., & Saddelli, M.
Venue
Nature Medicine
Published
2023-06-17
Volume
29
Issue
7
Pages
1867-1876
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4381052148
Cited by
171
References
21
FWCI
10.02
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. https://app.cochat.ai/papers/10.1038/s41591-023-02418-0
The paper
Inker, L. A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G. B., Badve, S. V., Caravaca-Fontán, F., Del Vecchio, L., Floege, J., Goicoechea, M., Haaland, B., Herrington, W. G., Imai, E., Jafar, T. H., Lewis, J. B., Li, P. K. T., Maes, B. D., Neuen, B. L., . . . Saddelli, M. (2023). A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nature Medicine. https://doi.org/10.1038/s41591-023-02418-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.